Ablynx - notice in relation to waiver of lock-up restriction

 

Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced that Merrill Lynch, Pierce, Fenner & Smith Incorporated, J.P. Morgan Securities LLC and Jefferies LLC, the lead book-running managers in the Company's recent public sale of 13,144,500 ordinary shares in the form of American Depositary Shares, including 1,714,500 ordinary shares from the full exercise of the underwriters' option, are waiving a lock-up restriction with respect to 18,750 ordinary shares of the Company held by an officer of the Company. The waiver will take effect on 29 December 2017 and the securities may be sold on or after such date. The purpose of the waiver is to allow the officer to make certain transfers for value to affiliated persons.

Note

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?